Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer

Not Applicable

Recruiting

• Conditions: Prostate Cancer

• Registration Number: NCT07180381
• Lead Sponsor: St. Antonius Hospital

Brief Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of immediate biopsy,.

The main questions it aims to answer are:

* Is it safe to delay biopsy, making sure that clinical significant prostate cancers are not often missed?

* Does it reduce unnecessary biopsies and overtreatment?

Detailed Description

Not available

Study Timeline

• Study Start: 2025-05-14
• Study First Submitted: 2025-07-16
• Status Verified: 2025-09
• Study First Submitted QC: 2025-09-11
• Last Update Submitted: 2025-09-11
• Study First Posted: 2025-09-18
• Last Update Posted: 2025-09-18
• Primary Completion: 2031-01
• Study Completion: 2031-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 503

Inclusion Criteria

• Life expectancy > 10 years
• initial PSA < 20 ng/ml
• No signs of extracapsular disease on digital rectal examination
• Intermediate-risk category for suspicion of prostate cancer determined by MRI results and PSA density (PSAD): PI-RADS 3 or PI-RADS 4 with PSAD =< 0.15
• Mentally competent and able to comprehend the potential benefits and burdens of the study
• Willing to undergo the follow-up protocol for a maximum of four years
• written and signed informed consent

Exclusion Criteria

• Men who have previously undergone a prostate biopsy
• Men who have a prior PCa diagnosis
• using any (anti-)hormonal therapy, including 5-alpha-reductase inhibitors
• Proven germline mutation for PCa (for example: BRCA1; BRCA2)
• Secondary malignancy, besides basal cell carcinoma of the skin, for which the potential participant is receiving active treatment at the time of inclusion.
• severe claustrofobia or other conditions that make (repeat) MRI unsuitable (e.g., metal implants, pacemakers)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Proportion clinically significant prostate cancer missed during follow up	48 months	Detection percentage of International Society of Urological Pathology Grade Group (ISUP GG)≥ 2 prostate cancer (= clinically significant prostate cancer) during 48 months of follow up compared with the percentage of total ISUP GG≥ 2 during the study, including any findings from end of study biopsies.; ISUP grade groups range from 1 to 5, and a ISUP GG≥ 2 is defined as clinically significant prostate cancer.
Number of clinically insignificant prostate cancer detected	48 months	Detection of clinically insignificant prostate cancer (International Society of Urological Pathology Grade Group (ISUP GG) 1) during the 48 months of follow up compared to the total ISUP GG 1 including end of study biopsies.
Number of negative biopsies	48 months	Number of participants with negative biopsy results during the study including findings from the end of study biopsies.

Secondary Outcome Measures

Name	Time	Method
Grade shifts	48 months	Progression rates of intermediate- to high-risk group during monitoring, rates of downgrading from intermediate risk to low risk
Detection of very high risk prostate cancer	48 months	Detection of very high risk prostate cancer (ISUP GG ≥ 3) during the study, including end of study biopsies.
Health-related quality of life (EPIC-26 score)	48 months	Change in health-related quality of life as measured by the Expanded Prostate Cancer Index Composite (EPIC-26), a validated questionnaire with subscales ranging from 0 to 100. Higher scores indicate better function and less symptom burden. Although the diagnosis of prostate cancer is not confirmed, this is the best validated and suitable questionnaire. Participants will be asked to fill in the questionnaire once a year.
Estimated average cost per patient during 48-month follow-up	48 months	Mean cost per participant over 48 months, including diagnostics (e.g. MRI, biopsies), consultations, and treatments, based on predefined unit costs and healthcare utilization.
Anxiety symptomes (STAI-6 score)	48 months	Change in anxiety levels as measured by the 6-item short form of the State-Trait Anxiety Inventory (STAI-6), with scores ranging from 20 to 80. Higher scores indicate greater anxiety. Participants will be asked to fill in the questionnaire once a year.

Trial Locations

Locations (6)

Andros Clinics; 🇳🇱 Arnhem, Gelderland, Netherlands

Radboud University Medical Centre; 🇳🇱 Nijmegen, Gelderland, Netherlands

Canisius Wilhelmina Hospital; 🇳🇱 Nijmegen, Gelderland, Netherlands

Antoni van Leeuwenhoek Hospital; 🇳🇱 Amsterdam, North Holland, Netherlands

Maasstad Hospital; 🇳🇱 Rotterdam, South Holland, Netherlands

St Antonius Hospital; 🇳🇱 Nieuwegein, Utrecht, Netherlands